Abstract
Our study demonstrate that HKC can inhibit kidney injury and oxidative stress injury in db/db mice and HK-2 cells by regulating tryptophan metabolism and the Keap1/Nrf2/HO-1 pathway, which provides new insight for the clinical use of HKC for treatment of DN.
Introduction
Diabetic nephropathy (DN) is a primary driver of end-stage renal disease globally. While standard treatments like ACE inhibitors and ARBs are commonly prescribed, they often fail to halt disease progression entirely. Traditional Chinese Medicines (TCMs), specifically Huangkui capsules (HKC) derived from Abelmoschus manihot, have shown clinical efficacy in treating kidney inflammation, but their precise molecular mechanisms have remained largely unknown. This study aims to bridge this gap by investigating how HKC influences metabolic signatures—specifically tryptophan metabolism—and how these changes translate into protection against the oxidative stress that damages diabetic kidneys.
Methods and Materials
The study employed a multi-layered approach combining systems biology with traditional molecular techniques:
- In Vivo Modeling: Researchers used db/db mice (a standard model for Type 2 diabetes) and compared them against healthy db/m controls. They tested two dosages of HKC against Irbesartan (IRB) as a positive control.
- Metabonomics: Using UHPLC-MS/MS, the team performed metabolic profiling of serum and urine from mice and human subjects (including healthy controls and patients with early and advanced DN) to identify disrupted pathways.
- In Vitro Verification: Human kidney epithelial (HK-2) cells were exposed to high glucose. The team introduced Sarpogrelate hydrochloride (SH), a 5-HT$_{2A}$R inhibitor, to verify if blocking the serotonin pathway could mimic HKC’s protective effects.
- Molecular Signaling: Assays were used to track the Keap1/Nrf2/HO-1 pathway, the cell's primary defense against oxidative damage.
Key Insights: The Tryptophan-Serotonin Connection
The most striking finding was that tryptophan metabolism is severely dysregulated in DN, shifting toward the production of serotonin (5-HT). While typically associated with the brain, peripheral serotonin in the kidney acts as a pro-oxidant and pro-fibrotic agent.
HKC acts as a metabolic regulator by rerouting this pathway, reducing the overproduction of 5-HT and its precursors. This metabolic shift is linked to the Nrf2 pathway; HKC promotes the dissociation of Nrf2 from its inhibitor (Keap1), allowing it to enter the nucleus and trigger the production of protective enzymes like HO-1. Validation using a serotonin receptor inhibitor (SH) proved that the 5-HT pathway is a primary driver of high-glucose-induced kidney injury, confirming HKC’s therapeutic target.
Key Results
HKC significantly improved renal function, reducing the Urinary Albumin/Creatinine Ratio (UACR) and blood glucose levels in db/db mice.
Treatment also reversed classic DN markers, including glomerular basement membrane thickening and collagen fiber accumulation. Gross morphological examination of the kidneys showed that HKC-treated mice maintained healthier organ structures compared to the untreated DN group.
Metabonomic analysis identified 5-HTP (a serotonin precursor) as a high-accuracy biomarker for DN (AUC = 0.9518), and HKC treatment successfully restored these levels toward baseline.
Limitations and Future Work
The authors acknowledge that while the 5-HT$_{2A}$R inhibitor was effective in vitro, corresponding in vivo trials are needed to confirm if pharmacological blockade of serotonin receptors is as effective as HKC in a living system. Furthermore, while the link between HKC and the Nrf2/5-HT axis is clear, the specific active compounds within the complex HKC extract remain to be fully isolated. Long-term clinical trials are necessary to determine if HKC can prevent the transition to end-stage renal failure in human populations.
Summary updated